This is a preview of subscription content, log in via an institution to check access.
Notes
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of treatment; the SMC advice is contingent upon the continuing availability of the PAS or a list price that is equivalent or lower.
Reference
Scottish Medicines Consortium. SMC advice: 5-aminolaevulinic acid (Ameluz); bortezomib (Velcade); lanthanum carbonate (Fosrenol); olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (Sevikar HCT); pazopanib (Votrient); perampanel (Fycompa); racecadotril (Hidrasec Infants, Hidrasec Children); ranibizumab (Lucentis); sildenafil (Revatio). Internet Document : 10 Dec 2012. Available from: URL: http://www.scottishmedicines.org.uk
Rights and permissions
About this article
Cite this article
Latest advice from the SMC. PharmacoEconomics & Outcomes News 669, 10 (2013). https://doi.org/10.1007/s40274-013-0065-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0065-7